Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03368872 · ClinicalTrials.gov registry record · NA

Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly

A NA study of Sarcopenia, sponsored by Astavita.

Completed
Registry status
NA
Development phase
41
Enrollment target
2
Study locations

NCT03368872 is a NA study of Sarcopenia that has completed, run by Astavita. The registered enrollment target is 41 participants, below the 79-participant average among 41 other Sarcopenia trials with a reported enrollment target (48% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03368872, a NA study of Sarcopenia, has completed, sponsored by Astavita.

COMPLETED
Registry status
NA
Development phase
41 participants
Enrollment target
2
Study locations

Study Summary

The primary objective of this trial is to evaluate the effect of oral administration of an Astaxanthin formulation compared to placebo after one month alone and after an additional 3 months of exercise training on mitochondrial and skeletal muscle function in elderly subjects with evidence of mitochondrial dysfunction/sarcopenia.

Conditions Studied

Interventions

  • OTHER Placebo
  • OTHER Exercise training
  • OTHER Astaxanthin formulation

Study Locations (2)

Washington

  • Fred Hutchinson Cancer Research Center Prevention Center - Seattle
  • University of Washington Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2015-10
Est. Completion 2016-08
Phase NA

Sponsor

Astavita

1 total trials

What the Registry Record Tells You About NCT03368872

The ClinicalTrials.gov registry entry for NCT03368872 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 41 other Sarcopenia trials with a reported enrollment target (48% lower). The listed sponsor is Astavita, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sarcopenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03368872 reports 2 study locations spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT03368872 about?

NCT03368872 is a clinical study titled "Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly". The primary objective of this trial is to evaluate the effect of oral administration of an Astaxanthin formulation compared to placebo after one month alone and after an additional 3 months of exercise training on mitochondrial and skeletal muscle function in elderly subjects with evidence of mitoch...

What is the current status of trial NCT03368872?

This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2015-10. Estimated completion is 2016-08.

What conditions does trial NCT03368872 study?

This clinical trial studies the following conditions: Sarcopenia.

What interventions are being tested in trial NCT03368872?

The interventions under investigation include: Placebo (OTHER), Exercise training (OTHER), Astaxanthin formulation (OTHER).

Who is sponsoring clinical trial NCT03368872?

This trial is sponsored by Astavita, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03368872 being conducted?

This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcopenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.